Archives: “Archives”

Showing 61 - 70 of 70 posts

Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort

https://www.coltonconsortium.org/publications/differences-in-disease-characteristics-and-treatment-exposures-between-paediatric-and-adult-onset-inflammatory-bowel-disease-using-a-registry-based-cohort/

A phase 3 trial of upadacitinib for giant-cell arteritis

https://www.coltonconsortium.org/publications/a-phase-3-trial-of-upadacitinib-for-giant-cell-arteritis/

A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe granulomatosis with polyangiitis

https://www.coltonconsortium.org/publications/a-randomized-double-blind-placebo-controlled-trial-of-abatacept-for-the-treatment-of-relapsing-non-severe-granulomatosis-with-polyangiitis/

Agent-based modeling for personalized prediction of an experimental immune response to immunotherapeutic antibodies

https://www.coltonconsortium.org/publications/agent-based-modeling-for-personalized-prediction-of-an-experimental-immune-response-to-immunotherapeutic-antibodies/

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

https://www.coltonconsortium.org/publications/chimeric-antigen-receptor-t-cells-against-the-ighv4-34-b-cell-receptor-specifically-eliminate-neoplastic-and-autoimmune-b-cells/

Yale Researchers Use Machine Learning Tool to Improve Personalized Immunotherapy Design

https://www.coltonconsortium.org/news/yale-researchers-use-machine-learning-to-improve-personalized-cancer-vaccine-design/

A Colton-supported Yale study has produced ImmunoStruct, a machine learning model that improves personalized cancer vaccine design by incorporating the 3D structure of immune-activating peptides — now licensed to a Yale spinout.

A New Research Hub for Autoimmunity and Immune Health at Penn Medicine

https://www.coltonconsortium.org/news/a-new-research-hub-for-autoimmunity-and-immune-health-at-penn-medicine/

Penn Medicine has opened a new research facility housing the Colton Center for Autoimmunity alongside immune health, vaccinology, and infectious disease teams — designed to accelerate breakthrough science through collaboration.

Inside the 2025 Colton Consortium Symposium: Driving Translational Research in Autoimmune Disease

https://www.coltonconsortium.org/news/inside-the-2025-colton-consortium-symposium-driving-translational-research-in-autoimmune-disease/

Global leaders in autoimmune research gathered for the 2025 Colton Consortium Symposium last month, sharing breakthroughs from foundational science to translational therapies and forging collaborations to improve patient lives worldwide.

Building the Future of Immune Health: Highlights from the 2025 Penn Colton Center Symposium

https://www.coltonconsortium.org/news/building-the-future-of-immune-health-highlights-from-the-2025-penn-colton-center-symposium/

The 2025 Penn Colton Center Symposium convened 150+ experts to explore breakthroughs in immune health and spotlight Penn's leadership, future headquarters, and innovations in autoimmunity research and precision medicine.

Penn Medicine’s Colton Center Is Driving the Next Immunotherapy Revolution — This Time for Autoimmune Disease

https://www.coltonconsortium.org/news/penn-medicines-colton-center-is-driving-the-next-immunotherapy-revolution-this-time-for-autoimmune-disease/

Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.